To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
530 Newest Publications in expert review of anticancer therapy
rss
The intriguing patterns of tumor response to trabectedin
03-05-2013 | Roberta Sanfilippo; Paolo G Casali, Expert Review of Anticancer Therapy, 2013
Among soft tissue sarcomas, myxoid liposarcomas are exceedingly sensitive to trabectedin. Obvious tumor shrinkage is seen in some patients, whereas nondimensional changes in tumor tissue are seen in others especially after the first cycles of therapy. These patterns of tumor response are ...
13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
03-05-2013 | Axel Le Cesne, Expert Review of Anticancer Therapy, 2013
Trabectedin (Yondelis® [PharmaMar S.A., Madrid, Spain]) is one of the most promising agents tested in the last two decades in patients with anthracycline/ifosfamide-resistant sarcomas and is the first agent highlighting the notion of prolonged tumor control in advanced soft tissue sarcoma. ...
Acknowledgements
03-05-2013 | Expert Review of Anticancer Therapy, 2013
Expert Review of Anticancer Therapy , June 2013, Vol. 13, No. 6s, Pages s31-s31.
A decade of change in the treatment of advanced soft tissue sarcoma
03-05-2013 | Jean-Yves Blay, Expert Review of Anticancer Therapy, 2013
Expert Review of Anticancer Therapy , June 2013, Vol. 13, No. 6s, Pages s1-s2.
Trabectedin’s contribution to the treatment of sarcomas
03-05-2013 | Jean-Yves Blay, Expert Review of Anticancer Therapy, 2013
Historically, treatment options for soft tissue sarcoma in adults have been limited. Prior to the introduction of trabectedin, only two main cytotoxic drugs were considered active: doxorubicin and ifosfamide (and to a lesser extent dacarbazine). Trabectedin is a unique marine-derived agent ...
Current questions in soft tissue sarcoma: further steps with Yondelis®
03-05-2013 | Peter Reichardt, Expert Review of Anticancer Therapy, 2013
Treatment of advanced soft tissue sarcoma remains a considerable therapeutic challenge. Doxorubicin-based combination therapy produces reasonable objective response rates but this comes at the cost of high associated toxicity in the absence of an overall survival benefit in the first-line ...
Current opinion on optimal treatment for colorectal cancer
25-04-2013 | Timothy J Price; Eva Segelov; Matthew Burge; Daniel G Haller; Stephen P Ackland; Niall C Tebbutt; Christos S Karapet ..., Expert Review of Anticancer Therapy, 2013
The medical treatment of colorectal cancer (CRC) has evolved greatly in the last 10years, involving complex combined chemotherapy protocols and, in more recent times, new biologic agents. Advances in adjuvant therapy have been limited to the addition of oxaliplatin and the substitution of ...
Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy?
25-04-2013 | Peter Storz, Expert Review of Anticancer Therapy, 2013
Expert Review of Anticancer Therapy , May 2013, Vol. 13, No. 5, Pages 501-504.
Acknowledgements
25-04-2013 | Expert Review of Anticancer Therapy, 2013
Expert Review of Anticancer Therapy , May 2013, Vol. 13, No. 5, Pages 637-637.
Vemurafenib in melanoma
25-04-2013 | Heather M Shaw; Paul D Nathan, Expert Review of Anticancer Therapy, 2013
The incidence of malignant melanoma is increasing annually. Early stages can be cured with surgical intervention but metastatic disease has generally had a dismal prognosis with few effective interventions. A half of all melanomas possess a BRAF mutation, which can be targeted by specific ...
Netmeeting
